299 related articles for article (PubMed ID: 23337525)
1. Economic and technological drivers of generic sterile injectable drug shortages.
Woodcock J; Wosinska M
Clin Pharmacol Ther; 2013 Feb; 93(2):170-6. PubMed ID: 23337525
[TBL] [Abstract][Full Text] [Related]
2. The Evolution of Supply and Demand in Markets for Generic Drugs.
Frank RG; McGuire TG; Nason I
Milbank Q; 2021 Sep; 99(3):828-852. PubMed ID: 34075623
[TBL] [Abstract][Full Text] [Related]
3. How the US Food and Drug Administration can solve the prescription drug shortage problem.
Schweitzer SO
Am J Public Health; 2013 May; 103(5):e10-4. PubMed ID: 23488502
[TBL] [Abstract][Full Text] [Related]
4. Critical drug shortages: implications for emergency medicine.
Mazer-Amirshahi M; Pourmand A; Singer S; Pines JM; van den Anker J
Acad Emerg Med; 2014 Jun; 21(6):704-11. PubMed ID: 25039558
[TBL] [Abstract][Full Text] [Related]
5. Addressing the Lack of Competition in Generic Drugs to Improve Healthcare Quality and Safety.
Sivashanker K; Fanikos J; Kachalia A
J Gen Intern Med; 2018 Nov; 33(11):2005-2007. PubMed ID: 30091120
[TBL] [Abstract][Full Text] [Related]
6. Drug shortages--a critical challenge for the generic-drug market.
Chabner BA
N Engl J Med; 2011 Dec; 365(23):2147-9. PubMed ID: 22040167
[No Abstract] [Full Text] [Related]
7. Generic Drugs in the United States: Policies to Address Pricing and Competition.
Gupta R; Shah ND; Ross JS
Clin Pharmacol Ther; 2019 Feb; 105(2):329-337. PubMed ID: 30471089
[TBL] [Abstract][Full Text] [Related]
8. Call to action: finding solutions for the drug shortage crisis in the United States.
Fox ER; Tyler LS
Clin Pharmacol Ther; 2013 Feb; 93(2):145-7. PubMed ID: 23337524
[TBL] [Abstract][Full Text] [Related]
9. High-cost generic drugs--implications for patients and policymakers.
Alpern JD; Stauffer WM; Kesselheim AS
N Engl J Med; 2014 Nov; 371(20):1859-62. PubMed ID: 25390739
[TBL] [Abstract][Full Text] [Related]
10. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
Li DG; Joyce C; Mostaghimi A
JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
[TBL] [Abstract][Full Text] [Related]
11. Drug shortages: a complex health care crisis.
Fox ER; Sweet BV; Jensen V
Mayo Clin Proc; 2014 Mar; 89(3):361-73. PubMed ID: 24582195
[TBL] [Abstract][Full Text] [Related]
12. Taking aim at shortages. Order strengthens FDA's enforcement authority.
Lee J
Mod Healthc; 2011 Nov; 41(45):10. PubMed ID: 22106770
[No Abstract] [Full Text] [Related]
13. Drugs, money, and power: the Canadian drug shortage.
Kaposy C
J Bioeth Inq; 2014 Mar; 11(1):85-9. PubMed ID: 24357073
[TBL] [Abstract][Full Text] [Related]
14. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
[TBL] [Abstract][Full Text] [Related]
15. [Competition between branded and generic drugs in Austria: evidence from the market for ACE inhibitors].
Mahlich JC; Stadler I
Gesundheitswesen; 2012 Jan; 74(1):23-8. PubMed ID: 21154203
[TBL] [Abstract][Full Text] [Related]
16. 'Biosimilar' drugs poised to penetrate market.
Ledford H
Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
[No Abstract] [Full Text] [Related]
17. Generic drugs: the stalling game.
Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
[TBL] [Abstract][Full Text] [Related]
18. Indian generics manufacturer Ranbaxy agrees to pay $500m to settle US fraud and drug safety charges.
Kay M
BMJ; 2013 May; 346():f3536. PubMed ID: 23723460
[No Abstract] [Full Text] [Related]
19. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
20. [Access for all to quality drugs].
Videau JY
Med Trop (Mars); 2002; 62(4):396-400. PubMed ID: 12534178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
